CoChat
Cited by 202

The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.

Glial Cell-Mediated Neuroinflammation in Alzheimer’s Disease

Open access
Al-Ghraiybah, Nour F., Wang, Junwei, Alkhalifa, Amer E., Roberts, Andrew B., Raj, Ruchika, Yang, Euitaek, Kaddoumi, Amal · 2022 · International Journal of Molecular Sciences

Abstract

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder; it is the most common cause of dementia and has no treatment. It is characterized by two pathological hallmarks, the extracellular deposits of amyloid beta (Aβ) and the intraneuronal deposits of Neurofibrillary tangles (NFTs). Yet, those two hallmarks do not explain the full pathology seen with AD, suggesting the involvement of other mechanisms. Neuroinflammation could offer another explanation for the progression of the disease. This review provides an overview of recent advances on the role of the immune cells’ microglia and astrocytes in neuroinflammation. In AD, microglia and astrocytes become reactive by several mechanisms leading to the release of proinflammatory cytokines that cause further neuronal damage. We then provide updates on neuroinflammation diagnostic markers and investigational therapeutics currently in clinical trials to target neuroinflammation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms231810572

Cites

103 of 103 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 103 references

Research works printed but not linked: 192

  1. Adav, 2016, Insight of brain degenerative protein modifications in the pathology of neurodegeneration and dementia by proteomic profiling, Mol. Brain, 9, 92, 10.1186/s13041-016-0272-9 · DOI
  2. Selkoe, 2000, Toward a comprehensive theory for Alzheimer’s disease. Hypothesis: Alzheimer’s disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein, Ann. N. Y. Acad. Sci., 924, 17, 10.1111/j.1749-6632.2000.tb05554.x · DOI · Paper page
  3. Patterson, C. (2018, January 21). Alzheimer’s Disease International (2018) World Alzheimer Report 2018. Proceedings of the the State of the Art of Dementia Research: New Frontiers, London, UK.
  4. Alzheimer’s Association (2021). 2021 Alzheimer’s disease facts and figures. Alzheimer’s Dement., 17, 327–406. · DOI · Paper page
  5. Hippius, 2022, The discovery of Alzheimer’s disease, Dialogues Clin. Neurosci., 5, 101, 10.31887/DCNS.2003.5.1/hhippius · DOI · Paper page
  6. Nordberg, 2015, Towards early diagnosis in Alzheimer disease, Nat. Rev. Neurol., 11, 69, 10.1038/nrneurol.2014.257 · DOI
  7. Massoud, 2011, Pharmacological treatment of Alzheimer disease, Can. J. Psychiatry, 56, 579, 10.1177/070674371105601003 · DOI
  8. Winslow, 2011, Treatment of Alzheimer disease, Am. Fam. Physician, 83, 1403
  9. Abeysinghe, 2020, Alzheimer’s disease; a review of the pathophysiological basis and therapeutic interventions, Life Sci., 256, 117996, 10.1016/j.lfs.2020.117996 · DOI · Paper page
  10. Frisoni, 2022, The probabilistic model of Alzheimer disease: The amyloid hypothesis revised, Nat. Rev. Neurosci., 23, 53, 10.1038/s41583-021-00533-w · DOI · Paper page
  11. Kwon, 2020, Neuroinflammation in neurodegenerative disorders: The roles of microglia and astrocytes, Transl. Neurodegener., 9, 42, 10.1186/s40035-020-00221-2 · DOI · Paper page
  12. Griciuc, 2021, The role of innate immune genes in Alzheimer’s disease, Curr. Opin. Neurol., 34, 228, 10.1097/WCO.0000000000000911 · DOI · Paper page
  13. Bachiller, 2018, Microglia in neurological diseases: A road map to brain-disease dependent-inflammatory response, Front. Cell. Neurosci., 12, 488, 10.3389/fncel.2018.00488 · DOI · Paper page
  14. Moser, 2016, Obesity and sex interact in the regulation of Alzheimer’s disease, Neurosci. Biobehav. Rev., 67, 102, 10.1016/j.neubiorev.2015.08.021 · DOI
  15. Maioli, 2021, Estrogen receptors and the aging brain, Essays Biochem., 65, 913, 10.1042/EBC20200162 · DOI
  16. Cui, 2013, Estrogen synthesis and signaling pathways during aging: From periphery to brain, Trends Mol. Med., 19, 197, 10.1016/j.molmed.2012.12.007 · DOI · Paper page
  17. Lee, 2014, Targeting Estrogen Receptors for the Treatment of Alzheimer’s Disease, Mol. Neurobiol., 49, 39, 10.1007/s12035-013-8484-9 · DOI
  18. Chakrabarti, 2014, Estrogen receptor agonists for attenuation of neuroinflammation and neurodegeneration, Brain Res. Bull., 109, 22, 10.1016/j.brainresbull.2014.09.004 · DOI
  19. 2021, Estrogenic hormones receptors in Alzheimer’s disease, Mol. Biol. Rep., 48, 7517, 10.1007/s11033-021-06792-1 · DOI
  20. Yun, 2018, Estrogen deficiency exacerbates Aβ-induced memory impairment through enhancement of neuroinflammation, amyloidogenesis and NF-κB activation in ovariectomized mice, Brain Behav. Immun., 73, 282, 10.1016/j.bbi.2018.05.013 · DOI
  21. Fuller, 2010, Activated astroglia during chronic inflammation in Alzheimer’s disease—Do they neglect their neurosupportive roles?, Mutat. Res. Fundam. Mol. Mech. Mutagenesis, 690, 40, 10.1016/j.mrfmmm.2009.08.016 · DOI
  22. Kloske, 2020, The Important Interface Between Apolipoprotein E and Neuroinflammation in Alzheimer’s Disease, Front. Immunol., 11, 754, 10.3389/fimmu.2020.00754 · DOI · Paper page
  23. Uddin, 2021, Exploring ER stress response in cellular aging and neuroinflammation in Alzheimer’s disease, Ageing Res. Rev., 70, 101417, 10.1016/j.arr.2021.101417 · DOI
  24. Carroll, 2011, Chronic stress exacerbates tau pathology, neurodegeneration, and cognitive performance through a corticotropin-releasing factor receptor-dependent mechanism in a transgenic mouse model of tauopathy, J. Neurosci., 31, 14436, 10.1523/JNEUROSCI.3836-11.2011 · DOI · Paper page
  25. Bondy, 2021, Metal toxicity and neuroinflammation, Curr. Opin. Toxicol., 26, 8, 10.1016/j.cotox.2021.03.008 · DOI
  26. Harischandra, 2019, Manganese-Induced Neurotoxicity: New Insights into the Triad of Protein Misfolding, Mitochondrial Impairment, and Neuroinflammation, Front Neurosci., 13, 654, 10.3389/fnins.2019.00654 · DOI · Paper page
  27. Huat, 2019, Metal Toxicity Links to Alzheimer’s Disease and Neuroinflammation, J. Mol. Biol., 431, 1843, 10.1016/j.jmb.2019.01.018 · DOI · Paper page
  28. Butterfield, 2018, Oxidative stress, amyloid-β peptide, and altered key molecular pathways in the pathogenesis and progression of Alzheimer’s disease, J. Alzheimer’s Dis., 62, 1345, 10.3233/JAD-170543 · DOI · Paper page
  29. Butterfield, 2002, Lipid peroxidation and protein oxidation in Alzheimer’s disease brain: Potential causes and consequences involving amyloid β-peptide-associated free radical oxidative stress, Free Radic. Biol. Med., 32, 1050, 10.1016/S0891-5849(02)00794-3 · DOI · Paper page
  30. Wang, 2014, Oxidative stress and mitochondrial dysfunction in Alzheimer’s disease, Biochim. Biophys. Acta (BBA)-Mol. Basis Dis., 1842, 1240, 10.1016/j.bbadis.2013.10.015 · DOI · Paper page
  31. Pawate, 2004, Redox regulation of glial inflammatory response to lipopolysaccharide and interferonγ, J. Neurosci. Res., 77, 540, 10.1002/jnr.20180 · DOI · Paper page
  32. Chan, 2001, Reactive oxygen radicals in signaling and damage in the ischemic brain, J. Cereb. Blood Flow Metab., 21, 2, 10.1097/00004647-200101000-00002 · DOI · Paper page
  33. Hsieh, 2013, Role of redox signaling in neuroinflammation and neurodegenerative diseases, BioMed Res. Int., 2013, 484613, 10.1155/2013/484613 · DOI · Paper page
  34. Saha, 2006, Regulation of inducible nitric oxide synthase gene in glial cells, Antioxid. Redox Signal., 8, 929, 10.1089/ars.2006.8.929 · DOI · Paper page
  35. Cavaliere, 2019, High-Fat Diet Induces Neuroinflammation and Mitochondrial Impairment in Mice Cerebral Cortex and Synaptic Fraction, Front. Cell. Neurosci., 13, 509, 10.3389/fncel.2019.00509 · DOI · Paper page
  36. McGrattan, 2019, Diet and Inflammation in Cognitive Ageing and Alzheimer’s Disease, Curr. Nutr. Rep., 8, 53, 10.1007/s13668-019-0271-4 · DOI · Paper page
  37. Lorena, 2021, Long-term obesity is associated with depression and neuroinflammation, Arch. Endocrinol. Metab., 65, 537, 10.20945/2359-3997000000400 · DOI
  38. Goyal, 2021, Emerging role of gut microbiota in modulation of neuroinflammation and neurodegeneration with emphasis on Alzheimer’s disease, Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 106, 110112, 10.1016/j.pnpbp.2020.110112 · DOI · Paper page
  39. Lin, 2022, Hydrogen-rich water ameliorates neuropathological impairments in a mouse model of Alzheimer’s disease through reducing neuroinflammation and modulating intestinal microbiota, Neural Regen. Res., 17, 409, 10.4103/1673-5374.317992 · DOI
  40. Solito, 2012, Microglia function in Alzheimer’s disease, Front. Pharmacol., 3, 14, 10.3389/fphar.2012.00014 · DOI · Paper page
  41. Zhang, 2021, Microglia in Alzheimer’s Disease: A Target for Therapeutic Intervention, Front. Cell. Neurosci., 15, 749587, 10.3389/fncel.2021.749587 · DOI
  42. Harry, 2008, Neuroinflammation and microglia: Considerations and approaches for neurotoxicity assessment, Expert Opin. Drug Metab. Toxicol., 4, 1265, 10.1517/17425255.4.10.1265 · DOI · Paper page
  43. Bianchi, 2020, The Role of P2X7 Receptor in Alzheimer’s Disease, Front. Mol. Neurosci., 13, 94, 10.3389/fnmol.2020.00094 · DOI
  44. Chen, 2021, The role of P2X7R in neuroinflammation and implications in Alzheimer’s disease, Life Sci., 271, 119187, 10.1016/j.lfs.2021.119187 · DOI
  45. Monif, 2010, Microglia: Proliferation and activation driven by the P2X7 receptor, Int. J. Biochem. Cell Biol., 42, 1753, 10.1016/j.biocel.2010.06.021 · DOI · Paper page
  46. Illes, 2019, The P2X7 receptor: A new therapeutic target in Alzheimer’s disease, Expert Opin. Ther. Targets, 23, 165, 10.1080/14728222.2019.1575811 · DOI
  47. Cai, 2016, Role of RAGE in Alzheimer’s Disease, Cell. Mol. Neurobiol., 36, 483, 10.1007/s10571-015-0233-3 · DOI · Paper page
  48. Liu, 2009, Upregulation of RAGE at the blood-brain barrier in streptozotocin-induced diabetic mice, Synapse, 63, 636, 10.1002/syn.20644 · DOI
  49. Abdallah, 2022, Oleuropein-Rich Olive Leaf Extract Attenuates Neuroinflammation in the Alzheimer’s Disease Mouse Model, ACS Chem. Neurosci., 13, 1002, 10.1021/acschemneuro.2c00005 · DOI
  50. Zhang, 2020, HMGB1/RAGE axis mediates stress-induced RVLM neuroinflammation in mice via impairing mitophagy flux in microglia, J. Neuroinflamm., 17, 15, 10.1186/s12974-019-1673-3 · DOI · Paper page
  51. Wang, 2020, RAGE Silencing Ameliorates Neuroinflammation by Inhibition of p38-NF-κB Signaling Pathway in Mouse Model of Parkinson’s Disease, Front. Neurosci., 14, 353, 10.3389/fnins.2020.00353 · DOI
  52. Baiguera, 2009, Involvement of the receptor for advanced glycation-end products (RAGE) in beta-amyloid-induced toxic effects in rat cerebromicrovascular endothelial cells cultured in vitro, Int. J. Mol. Med., 24, 9
  53. Magna, 2014, The role of HMGB1 in the pathogenesis of inflammatory and autoimmune diseases, Mol. Med., 20, 138, 10.2119/molmed.2013.00164 · DOI · Paper page
  54. Son, 2017, Ligands of Receptor for Advanced Glycation End-Products Produced by Activated Microglia are Critical in Neurodegenerative Diseases, J. Alzheimer’s Dis. Parkinsonism, 7, 1000318
  55. Prasad, 2019, AGE–RAGE stress: A changing landscape in pathology and treatment of Alzheimer’s disease, Mol. Cell. Biochem., 459, 95, 10.1007/s11010-019-03553-4 · DOI
  56. Cella, 2022, Improved Sleep, Memory, and Cellular Pathological Features of Tauopathy, Including the NLRP3 Inflammasome, after Chronic Administration of Trazodone in rTg4510 Mice, J. Neurosci., 42, 3494, 10.1523/JNEUROSCI.2162-21.2022 · DOI
  57. He, 2020, NLRP3-dependent microglial training impaired the clearance of amyloid-beta and aggravated the cognitive decline in Alzheimer’s disease, Cell Death Dis., 11, 849, 10.1038/s41419-020-03072-x · DOI
  58. Feng, 2020, The involvement of NLRP3 inflammasome in the treatment of Alzheimer’s disease, Ageing Res. Rev., 64, 101192, 10.1016/j.arr.2020.101192 · DOI · Paper page
  59. Sheng, 2001, Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer’s disease: Potential significance for tau protein phosphorylation, Neurochem. Int., 39, 341, 10.1016/S0197-0186(01)00041-9 · DOI · Paper page
  60. Mitroulis, 2010, Targeting IL-1β in disease; the expanding role of NLRP3 inflammasome, Eur. J. Intern. Med., 21, 157, 10.1016/j.ejim.2010.03.005 · DOI
  61. Sharma, B., Satija, G., Madan, A., Garg, M., Alam, M.M., Shaquiquzzaman, M., Khanna, S., Tiwari, P., Parvez, S., and Iqubal, A. (2022). Role of NLRP3 Inflammasome and Its Inhibitors as Emerging Therapeutic Drug Candidate for Alzheimer’s Disease: A Review of Mechanism of Activation, Regulation, and Inhibition. Inflammation, 1–32. · DOI
  62. Barczuk, J., Siwecka, N., Lusa, W., Rozpędek-Kamińska, W., Kucharska, E., and Majsterek, I. (2022). Targeting NLRP3-Mediated Neuroinflammation in Alzheimer’s Disease Treatment. Int. J. Mol. Sci., 23. · DOI
  63. Ellwanger, 2021, Prior activation state shapes the microglia response to antihuman TREM2 in a mouse model of Alzheimer’s disease, Proc. Natl. Acad. Sci. USA, 118, e2017742118, 10.1073/pnas.2017742118 · DOI · Paper page
  64. Hu, 2014, Increased expression of TREM2 in peripheral blood of Alzheimer’s disease patients, J. Alzheimer’s Dis., 38, 497, 10.3233/JAD-130854 · DOI
  65. Karanfilian, 2020, The role of TREM2 in Alzheimer’s disease; evidence from transgenic mouse models, Neurobiol. Aging, 86, 39, 10.1016/j.neurobiolaging.2019.09.004 · DOI
  66. Jairaman, 2022, TREM2 regulates purinergic receptor-mediated calcium signaling and motility in human iPSC-derived microglia, eLife, 11, e73021, 10.7554/eLife.73021 · DOI
  67. Ruganzu, 2022, Downregulation of TREM2 expression exacerbates neuroinflammatory responses through TLR4-mediated MAPK signaling pathway in a transgenic mouse model of Alzheimer’s disease, Mol. Immunol., 142, 22, 10.1016/j.molimm.2021.12.018 · DOI
  68. Long, 2019, TREM2 Attenuates Aβ1-42-Mediated Neuroinflammation in BV-2 Cells by Downregulating TLR Signaling, Neurochem. Res., 44, 1830, 10.1007/s11064-019-02817-1 · DOI
  69. Serra, 2015, Uncovering Neurodegenerative Protein Modifications via Proteomic Profiling, Int. Rev. Neurobiol., 121, 87, 10.1016/bs.irn.2015.06.002 · DOI
  70. Tilvawala, 2018, The Rheumatoid Arthritis-Associated Citrullinome, Cell Chem. Biol., 25, 691, 10.1016/j.chembiol.2018.03.002 · DOI · Paper page
  71. Mukherjee, 2021, Citrullination of Amyloid-β Peptides in Alzheimer’s Disease, ACS Chem. Neurosci., 12, 3719, 10.1021/acschemneuro.1c00474 · DOI
  72. Serra, 2017, Brain ureido degenerative protein modifications are associated with neuroinflammation and proteinopathy in Alzheimer’s disease with cerebrovascular disease, J. Neuroinflamm., 14, 175, 10.1186/s12974-017-0946-y · DOI
  73. Ishigami, 2015, Mass spectrometric identification of citrullination sites and immunohistochemical detection of citrullinated glial fibrillary acidic protein in Alzheimer’s disease brains, J. Neurosci. Res., 93, 1664, 10.1002/jnr.23620 · DOI
  74. Joshi, 2021, Differential interaction with TREM2 modulates microglial uptake of modified Aβ species, Glia, 69, 2917, 10.1002/glia.24077 · DOI
  75. Kumar, 2020, Novel Phosphorylation-State Specific Antibodies Reveal Differential Deposition of Ser26 Phosphorylated Aβ Species in a Mouse Model of Alzheimer’s Disease, Front. Mol. Neurosci., 13, 619639, 10.3389/fnmol.2020.619639 · DOI
  76. Becker, 2016, IsoQC (QPCTL) knock-out mice suggest differential substrate conversion by glutaminyl cyclase isoenzymes, Biol. Chem., 397, 45, 10.1515/hsz-2015-0192 · DOI
  77. Hinojosa, 2011, CCL2/MCP-1 modulation of microglial activation and proliferation, J. Neuroinflamm., 8, 77, 10.1186/1742-2094-8-77 · DOI · Paper page
  78. Kiyota, T., Yamamoto, M., Xiong, H., Lambert, M.P., Klein, W.L., Gendelman, H.E., Ransohoff, R.M., and Ikezu, T. (2009). CCL2 accelerates microglia-mediated Abeta oligomer formation and progression of neurocognitive dysfunction. PLoS ONE, 4. · DOI · Paper page
  79. Waniek, 2015, Isoglutaminyl cyclase contributes to CCL2-driven neuroinflammation in Alzheimer’s disease, Acta Neuropathol., 129, 565, 10.1007/s00401-015-1395-2 · DOI
  80. Siracusa, 2019, Astrocytes: Role and functions in brain pathologies, Front. Pharmacol., 10, 1114, 10.3389/fphar.2019.01114 · DOI · Paper page
  81. Uddin, 2020, Pharmacological approaches to mitigate neuroinflammation in Alzheimer’s disease, Int. Immunopharmacol., 84, 106479, 10.1016/j.intimp.2020.106479 · DOI
  82. 2017, Involvement of astrocytes in Alzheimer’s disease from a neuroinflammatory and oxidative stress perspective, Front. Mol. Neurosci., 10, 427, 10.3389/fnmol.2017.00427 · DOI · Paper page
  83. Leng, K., Rooney, B., Kim, H., Xia, W., Koontz, M., Krawczyk, M., Zhang, Y., Ullian, E.M., Fancy, S.P., and Schrag, M.S. (2021). CRISPRi screens in human astrocytes elucidate regulators of distinct inflammatory reactive states. BioRxiv. · DOI
  84. Lv, 2014, Quantitative proteomics reveals that PEA15 regulates astroglial Aβ phagocytosis in an Alzheimer’s disease mouse model, J. Proteom., 110, 45, 10.1016/j.jprot.2014.07.028 · DOI
  85. Li, Y., Cheng, D., Cheng, R., Zhu, X., Wan, T., Liu, J., and Zhang, R. (2014). Mechanisms of U87 astrocytoma cell uptake and trafficking of monomeric versus protofibril Alzheimer’s disease amyloid-β proteins. PLoS ONE, 9. · DOI
  86. Steiner, 2011, S100B protein in neurodegenerative disorders, Clin. Chem. Lab. Med., 49, 409, 10.1515/CCLM.2011.083 · DOI
  87. Son, 2015, Statins induce insulin-degrading enzyme secretion from astrocytes via an autophagy-based unconventional secretory pathway, Mol. Neurodegener., 10, 56, 10.1186/s13024-015-0054-3 · DOI
  88. Yamamoto, 2014, Leptin inhibits amyloid β-protein degradation through decrease of neprilysin expression in primary cultured astrocytes, Biochem. Biophys. Res. Commun., 445, 214, 10.1016/j.bbrc.2014.01.168 · DOI
  89. Nagele, 2004, Contribution of glial cells to the development of amyloid plaques in Alzheimer’s disease, Neurobiol. Aging, 25, 663, 10.1016/j.neurobiolaging.2004.01.007 · DOI · Paper page
  90. Johnston, 2006, Calcium oscillations in type-1 astrocytes, the effect of a presenilin 1 (PS1) mutation, Neurosci. Lett., 395, 159, 10.1016/j.neulet.2005.10.088 · DOI
  91. Batarseh, Y.S., Duong, Q.-V., Mousa, Y.M., Al Rihani, S.B., Elfakhri, K., and Kaddoumi, A. (2016). Amyloid-β and astrocytes interplay in amyloid-β related disorders. Int. J. Mol. Sci., 17. · DOI
  92. Oksanen, 2020, NF-E2-related factor 2 activation boosts antioxidant defenses and ameliorates inflammatory and amyloid properties in human Presenilin-1 mutated Alzheimer’s disease astrocytes, Glia, 68, 589, 10.1002/glia.23741 · DOI
  93. Jeong, 2018, Real-time monitoring of glutathione in living cells reveals that high glutathione levels are required to maintain stem cell function, Stem Cell Rep., 10, 600, 10.1016/j.stemcr.2017.12.007 · DOI
  94. Chen, 2022, Altered central and blood glutathione in Alzheimer’s disease and mild cognitive impairment: A meta-analysis, Alzheimer’s Res. Ther., 14, 23, 10.1186/s13195-022-00961-5 · DOI
  95. Aksenov, 2001, Changes in thiol content and expression of glutathione redox system genes in the hippocampus and cerebellum in Alzheimer’s disease, Neurosci. Lett., 302, 141, 10.1016/S0304-3940(01)01636-6 · DOI · Paper page
  96. Gu, 2015, Glutathione redox imbalance in brain disorders, Curr. Opin. Clin. Nutr. Metab. Care, 18, 89, 10.1097/MCO.0000000000000134 · DOI · Paper page
  97. Pocernich, 2012, Elevation of glutathione as a therapeutic strategy in Alzheimer disease, Biochim. Et Biophys. Acta (BBA)-Mol. Basis Dis., 1822, 625, 10.1016/j.bbadis.2011.10.003 · DOI · Paper page
  98. Lee, 2010, Depletion of GSH in glial cells induces neurotoxicity: Relevance to aging and degenerative neurological diseases, FASEB J., 24, 2533, 10.1096/fj.09-149997 · DOI · Paper page
  99. Takahashi, S. (2021). Neuroprotective Function of High Glycolytic Activity in Astrocytes: Common Roles in Stroke and Neurodegenerative Diseases. Int. J. Mol. Sci., 22. · DOI
  100. Baxter, 2016, Adaptive regulation of the brain’s antioxidant defences by neurons and astrocytes, Free Radic. Biol. Med., 100, 147, 10.1016/j.freeradbiomed.2016.06.027 · DOI · Paper page
  101. Chen, 2001, Astrocytes protect neurons from nitric oxide toxicity by a glutathione-dependent mechanism, J. Neurochem., 77, 1601, 10.1046/j.1471-4159.2001.00374.x · DOI · Paper page
  102. Aoyama, K. (2021). Glutathione in the Brain. Int. J. Mol. Sci., 22. · DOI · Paper page
  103. Acosta, 2017, Astrocyte dysfunction in Alzheimer disease, J. Neurosci. Res., 95, 2430, 10.1002/jnr.24075 · DOI · Paper page
  104. Steele, 2012, Reactive astrocytes give neurons less support: Implications for Alzheimer’s disease, Neurobiol. Aging, 33, 423.e1, 10.1016/j.neurobiolaging.2010.09.018 · DOI
  105. Bernacki, 2008, Physiology and pharmacological role of the blood-brain barrier, Pharmacol. Rep. PR, 60, 600
  106. Hawkins, 2008, Pathophysiology of the blood-brain barrier: Animal models and methods, Curr. Top. Dev. Biol., 80, 277, 10.1016/S0070-2153(07)80007-X · DOI
  107. Sharma, C., Woo, H., and Kim, S.R. (2022). Addressing Blood–Brain Barrier Impairment in Alzheimer’s Disease. Biomedicines, 10. · DOI
  108. Choi, 2019, NF-κB as a Key Mediator of Brain Inflammation in Alzheimer’s Disease, CNS Neurol. Disord. Drug Targets, 18, 3, 10.2174/1871527316666170807130011 · DOI · Paper page
  109. Yang, S., Magnutzki, A., Alami, N.O., Lattke, M., Hein, T.M., Scheller, J.S., Kröger, C., Oswald, F., Yilmazer-Hanke, D., and Wirth, T. (2021). IKK2/NF-κB Activation in Astrocytes Reduces amyloid β Deposition: A Process Associated with Specific Microglia Polarization. Cells, 10. · DOI
  110. Sibaii, 2019, Toll-like receptors activation, signaling, and targeting: An overview, Bull. Natl. Res. Cent., 43, 187, 10.1186/s42269-019-0227-2 · DOI · Paper page
  111. Frederiksen, 2019, Cell Type Specific Expression of Toll-Like Receptors in Human Brains and Implications in Alzheimer’s Disease, BioMed Res. Int., 2019, 7420189, 10.1155/2019/7420189 · DOI · Paper page
  112. Walker, 2018, Increased expression of toll-like receptor 3, an anti-viral signaling molecule, and related genes in Alzheimer’s disease brains, Exp. Neurol., 309, 91, 10.1016/j.expneurol.2018.07.016 · DOI
  113. Leitner, 2019, Targeting toll-like receptor 4 to modulate neuroinflammation in central nervous system disorders, Expert Opin. Ther. Targets, 23, 865, 10.1080/14728222.2019.1676416 · DOI · Paper page
  114. Dallas, 2021, TLR2 and TLR4-mediated inflammation in Alzheimer’s disease: Self-defense or sabotage?, Neural Regen. Res., 16, 1552, 10.4103/1673-5374.303016 · DOI
  115. Ioghen, 2021, CD36—A novel molecular target in the neurovascular unit, Eur. J. Neurosci., 53, 2500, 10.1111/ejn.15147 · DOI · Paper page
  116. Sankar, 2018, Heme and hemoglobin suppress amyloid β-mediated inflammatory activation of mouse astrocytes, J. Biol. Chem., 293, 11358, 10.1074/jbc.RA117.001050 · DOI
  117. Klug, 2017, Intramembrane attenuation of the TLR4-TLR6 dimer impairs receptor assembly and reduces microglia-mediated neurodegeneration, J. Biol. Chem., 292, 13415, 10.1074/jbc.M117.784983 · DOI
  118. Uekawa, 2018, Abstract 149: CD36 in Perivascular Macrophages Contributes to Neurovascular and Cognitive Dysfunction and Amyloid Angiopathy in Mice Overexpressing the Alzheimer Aβ Peptide, Stroke, 49, A149, 10.1161/str.49.suppl_1.149 · DOI
  119. Aymerich, 2018, Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system, Biochem. Pharmacol., 157, 67, 10.1016/j.bcp.2018.08.016 · DOI
  120. Rothlin, 2015, TAM Receptor Signaling in Immune Homeostasis, Annu. Rev. Immunol., 33, 355, 10.1146/annurev-immunol-032414-112103 · DOI · Paper page
  121. Wilson, 2021, TAM-ping down amyloid in Alzheimer’s disease, Nat. Immunol., 22, 543, 10.1038/s41590-021-00918-0 · DOI
  122. Varley, 2015, Imaging neuroinflammation in Alzheimer’s disease and other dementias: Recent advances and future directions, Alzheimer’s Dement., 11, 1110, 10.1016/j.jalz.2014.08.105 · DOI
  123. Gaetani, 2020, CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment, Trends Pharmacol. Sci., 41, 1023, 10.1016/j.tips.2020.09.011 · DOI
  124. Park, 2020, Peripheral inflammatory biomarkers in Alzheimer’s disease: A brief review, BMB Rep., 53, 10, 10.5483/BMBRep.2020.53.1.309 · DOI · Paper page
  125. Snellman, 2018, Neuroinflammation Appears Early on PET Imaging and Then Plateaus in a Mouse Model of Alzheimer Disease, J. Nucl. Med., 59, 509, 10.2967/jnumed.117.197608 · DOI
  126. Lagarde, 2018, In vivo PET imaging of neuroinflammation in Alzheimer’s disease, J. Neural Transm., 125, 847, 10.1007/s00702-017-1731-x · DOI
  127. Werry, E.L., Bright, F.M., Piguet, O., Ittner, L.M., Halliday, G.M., Hodges, J.R., Kiernan, M.C., Loy, C.T., Kril, J.J., and Kassiou, M. (2019). Recent Developments in TSPO PET Imaging as A Biomarker of Neuroinflammation in Neurodegenerative Disorders. Int. J. Mol. Sci., 20. · DOI · Paper page
  128. Tournier, 2020, Astrocytic TSPO Upregulation Appears Before Microglial TSPO in Alzheimer’s Disease, J. Alzheimer’s Dis., 77, 1043, 10.3233/JAD-200136 · DOI · Paper page
  129. Tournier, 2019, TSPO and amyloid deposits in sub-regions of the hippocampus in the 3xTgAD mouse model of Alzheimer’s disease, Neurobiol. Dis., 121, 95, 10.1016/j.nbd.2018.09.022 · DOI · Paper page
  130. Zhou, 2021, PET Imaging of Neuroinflammation in Alzheimer’s Disease, Front. Immunol., 12, 739130, 10.3389/fimmu.2021.739130 · DOI
  131. Park, 2020, New fluid biomarkers tracking non-amyloid-β and non-tau pathology in Alzheimer’s disease, Exp. Mol. Med., 52, 556, 10.1038/s12276-020-0418-9 · DOI
  132. Mavroudis, I., Chowdhury, R., Petridis, F., Karantali, E., Chatzikonstantinou, S., Balmus, I.M., Luca, I.S., Ciobica, A., and Kazis, D. (2022). YKL-40 as a Potential Biomarker for the Differential Diagnosis of Alzheimer’s Disease. Medicina, 58. · DOI
  133. Hoozemans, 2022, YKL-40 changes are not detected in post-mortem brain of patients with Alzheimer’s disease and frontotemporal lobar degeneration, Alzheimer’s Res. Ther., 14, 100, 10.1186/s13195-022-01039-y · DOI
  134. Angiulli, F., Conti, E., Zoia, C.P., Da Re, F., Appollonio, I., Ferrarese, C., and Tremolizzo, L. (2021). Blood-Based Biomarkers of Neuroinflammation in Alzheimer’s Disease: A Central Role for Periphery?. Diagnostics, 11. · DOI
  135. Bekris, 2018, Soluble TREM2 and biomarkers of central and peripheral inflammation in neurodegenerative disease, J. Neuroimmunol., 319, 19, 10.1016/j.jneuroim.2018.03.003 · DOI
  136. Xu, 2021, Neuroinflammation modulates the association of PGRN with cerebral amyloid-β burden, Neurobiol. Aging, 103, 52, 10.1016/j.neurobiolaging.2021.02.016 · DOI
  137. Molinuevo, 2019, Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer’s disease, Ther. Adv. Neurol. Disord., 12, 1756286419888819
  138. Drake, 2020, Peripheral markers of vascular endothelial dysfunction show independent but additive relationships with brain-based biomarkers in association with functional impairment in Alzheimer’s disease, Alzheimer’s Dement., 16, e046554, 10.1002/alz.046554 · DOI
  139. Wang, 2021, The neuroinflammation signatures in different stages of the Alzheimer’s disease continuum, Alzheimer’s Dement., 17, e055183, 10.1002/alz.055183 · DOI
  140. Lee, 2018, Plasma MCP-1 and Cognitive Decline in Patients with Alzheimer’s Disease and Mild Cognitive Impairment: A Two-year Follow-up Study, Sci. Rep., 8, 1280, 10.1038/s41598-018-19807-y · DOI · Paper page
  141. Olsson, 2016, CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: A systematic review and meta-analysis, Lancet Neurol., 15, 673, 10.1016/S1474-4422(16)00070-3 · DOI · Paper page
  142. Singh, 2021, MCP-1: Function, regulation, and involvement in disease, Int. Immunopharmacol., 101, 107598, 10.1016/j.intimp.2021.107598 · DOI · Paper page
  143. Fong, 2019, Delirium and Alzheimer disease: A proposed model for shared pathophysiology, Int. J. Geriatr. Psychiatry, 34, 781, 10.1002/gps.5088 · DOI
  144. Peskind, 2001, Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer’s disease, Neurochem. Int., 39, 409, 10.1016/S0197-0186(01)00048-1 · DOI · Paper page
  145. Petzold, 2003, Cerebrospinal fluid S100B correlates with brain atrophy in Alzheimer’s disease, Neurosci. Lett., 336, 167, 10.1016/S0304-3940(02)01257-0 · DOI
  146. Zuliani, 2008, Markers of endothelial dysfunction in older subjects with late onset Alzheimer’s disease or vascular dementia, J. Neurol. Sci., 272, 164, 10.1016/j.jns.2008.05.020 · DOI · Paper page
  147. Janssen, 2019, Development of brain PET imaging agents: Strategies for imaging neuroinflammation in Alzheimer’s disease, Prog. Mol. Biol. Transl. Sci., 165, 371, 10.1016/bs.pmbts.2019.04.005 · DOI
  148. McGrowder, D.A., Miller, F., Vaz, K., Nwokocha, C., Wilson-Clarke, C., Anderson-Cross, M., Brown, J., Anderson-Jackson, L., Williams, L., and Latore, L. (2021). Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease: Current Evidence and Future Perspectives. Brain Sci., 11. · DOI · Paper page
  149. Mcgeer, 1990, Anti-inflammatory drugs and Alzheimer disease, Lancet, 335, 1037, 10.1016/0140-6736(90)91101-F · DOI · Paper page
  150. Breitner, 1996, Inflammatory processes and antiinflammatory drugs in Alzheimer’s disease: A current appraisal, Neurobiol. Aging, 17, 789, 10.1016/0197-4580(96)00109-1 · DOI · Paper page
  151. Ozben, 2019, Neuro-inflammation and anti-inflammatory treatment options for Alzheimer’s disease, Clin. Biochem., 72, 87, 10.1016/j.clinbiochem.2019.04.001 · DOI · Paper page
  152. Maslyar, 2022, A Phase 1 Study of AL003 in Healthy Volunteers and Participants with Alzheimer’s disease (P5-3.002), Neurology, 98, 3582, 10.1212/WNL.98.18_supplement.3582 · doi:10.1212/wnl.98.18_supplement.3582
  153. Ko, 2015, The anti-inflammatory effect of human telomerase-derived peptide on P. gingivalis lipopolysaccharide-induced inflammatory cytokine production and its mechanism in human dental pulp cells, Mediat. Inflamm., 2015, 385217, 10.1155/2015/385127 · DOI
  154. Koeken, 2020, BCG vaccination in humans inhibits systemic inflammation in a sex-dependent manner, J. Clin. Investig., 130, 5591, 10.1172/JCI133935 · DOI · Paper page
  155. Klinger, D., Hill, B.L., Barda, N., Halperin, E., Gofrit, O.N., Greenblatt, C.L., Rappoport, N., Linial, M., and Bercovier, H. (2021). Bladder cancer immunotherapy by BCG is associated with a significantly reduced risk of Alzheimer’s disease and Parkinson’s disease. Vaccines, 9. · doi:10.1101/2021.01.30.21250811
  156. Li, 2003, Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway, J. Neurosci., 23, 1605, 10.1523/JNEUROSCI.23-05-01605.2003 · DOI · Paper page
  157. Birnbaum, 2015, Calcium flux-independent NMDA receptor activity is required for Aβ oligomer-induced synaptic loss, Cell Death Dis., 6, e1791, 10.1038/cddis.2015.160 · DOI
  158. Koppensteiner, 2016, Time-dependent reversal of synaptic plasticity induced by physiological concentrations of oligomeric Aβ42: An early index of Alzheimer’s disease, Sci. Rep., 6, 32553, 10.1038/srep32553 · DOI
  159. Gee, 2020, A selective p38α/β MAPK inhibitor alleviates neuropathology and cognitive impairment, and modulates microglia function in 5XFAD mouse, Alzheimer’s Res. Ther., 12, 45, 10.1186/s13195-020-00617-2 · DOI
  160. Duffy, 2011, The Discovery of VX-745: A Novel and Selective p38α Kinase Inhibitor, ACS Med. Chem. Lett., 2, 758, 10.1021/ml2001455 · DOI
  161. Alam, 2015, Selective Brain-Targeted Antagonism of p38 MAPKα Reduces Hippocampal IL-1β Levels and Improves Morris Water Maze Performance in Aged Rats, J. Alzheimer’s Dis. JAD, 48, 219, 10.3233/JAD-150277 · DOI
  162. Lee, 2000, p38 MAP kinase regulates TNF-α production in human astrocytes and microglia by multiple mechanisms, Cytokine, 12, 874, 10.1006/cyto.2000.0688 · DOI
  163. Kim, 2004, Importance of MAPK pathways for microglial pro-inflammatory cytokine IL-1β production, Neurobiol. Aging, 25, 431, 10.1016/S0197-4580(03)00126-X · DOI · Paper page
  164. McDonald, 1998, β-Amyloid fibrils activate parallel mitogen-activated protein kinase pathways in microglia and THP1 monocytes, J. Neurosci., 18, 4451, 10.1523/JNEUROSCI.18-12-04451.1998 · DOI · Paper page
  165. Pierrat, 1997, Blockade of p38 mitogen-activated protein kinase pathway inhibits inducible nitric-oxide synthase expression in mouse astrocytes, J. Biol. Chem., 272, 28373, 10.1074/jbc.272.45.28373 · DOI · Paper page
  166. Hua, 2002, Role of mitogen-activated protein kinases in inducible nitric oxide synthase and TNFα expression in human fetal astrocytes, J. Neuroimmunol., 126, 180, 10.1016/S0165-5728(02)00055-3 · DOI
  167. Han, 2017, Microglia-derived IL-1β contributes to axon development disorders and synaptic deficit through p38-MAPK signal pathway in septic neonatal rats, J. Neuroinflamm., 14, 52, 10.1186/s12974-017-0805-x · DOI
  168. Lim, 2000, Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer’s disease, J. Neurosci., 20, 5709, 10.1523/JNEUROSCI.20-15-05709.2000 · DOI · Paper page
  169. Wilkinson, 2012, Ibuprofen attenuates oxidative damage through NOX2 inhibition in Alzheimer’s disease, Neurobiol. Aging, 33, 197.e21, 10.1016/j.neurobiolaging.2010.06.014 · DOI
  170. Green, 2020, To kill a microglia: A case for CSF1R inhibitors, Trends Immunol., 41, 771, 10.1016/j.it.2020.07.001 · DOI · Paper page
  171. Elfakhri, 2019, Multi-faceted therapeutic strategy for treatment of Alzheimer’s disease by concurrent administration of etodolac and α-tocopherol, Neurobiol. Dis., 125, 123, 10.1016/j.nbd.2019.01.020 · DOI
  172. Gardener, 2018, Mediterranean diet in preventing neurodegenerative diseases, Curr. Nutr. Rep., 7, 10, 10.1007/s13668-018-0222-5 · DOI · Paper page
  173. Loued, 2013, Extra-virgin olive oil consumption reduces the age-related decrease in HDL and paraoxonase 1 anti-inflammatory activities, Br. J. Nutr., 110, 1272, 10.1017/S0007114513000482 · DOI
  174. Fezai, 2013, Analgesic, anti-inflammatory and anticancer activities of extra virgin olive oil, J. Lipids, 2013, 129736, 10.1155/2013/129736 · DOI
  175. Kleemann, 2018, Extra-virgin olive oil with natural phenolic content exerts an anti-inflammatory effect in adipose tissue and attenuates the severity of atherosclerotic lesions in Ldlr−/−. Leiden mice, Mol. Nutr. Food Res., 62, 1800295, 10.1002/mnfr.201800295 · DOI
  176. Mahmoud, 2021, Anti-inflammatory effects of evening primrose and extra virgin olive oil on arthritc rats, Adv. Anim. Vet. Sci., 9, 1684, 10.17582/journal.aavs/2021/9.10.1684.1691 · doi:10.17582/journal.aavs/2021/9.10.1684.1691
  177. Serreli, G., and Deiana, M. (2020). Extra virgin olive oil polyphenols: Modulation of cellular pathways related to oxidant species and inflammation in aging. Cells, 9. · DOI
  178. Negro, C., Aprile, A., Luvisi, A., Nicolì, F., Nutricati, E., Vergine, M., Miceli, A., Blando, F., Sabella, E., and De Bellis, L. (2019). Phenolic profile and antioxidant activity of Italian monovarietal extra virgin olive oils. Antioxidants, 8. · DOI
  179. Batarseh, 2018, Oleocanthal-rich extra-virgin olive oil enhances donepezil effect by reducing amyloid-β load and related toxicity in a mouse model of Alzheimer’s disease, J. Nutr. Biochem., 55, 113, 10.1016/j.jnutbio.2017.12.006 · DOI
  180. Qosa, 2015, Oleocanthal enhances amyloid-β clearance from the brains of TgSwDI mice and in vitro across a human blood-brain barrier model, ACS Chem. Neurosci., 6, 1849, 10.1021/acschemneuro.5b00190 · DOI
  181. Darakjian, 2019, Oleocanthal-rich extra-virgin olive oil restores the blood–brain barrier function through NLRP3 inflammasome inhibition simultaneously with autophagy induction in TgSwDI mice, ACS Chem. Neurosci., 10, 3543, 10.1021/acschemneuro.9b00175 · DOI
  182. Tsolaki, 2020, A randomized clinical trial of greek high phenolic early harvest extra virgin olive oil in mild cognitive impairment: The MICOIL pilot study, J. Alzheimer’s Dis., 78, 801, 10.3233/JAD-200405 · DOI
  183. Tzekaki, 2021, Restoration of BMI1 levels after the administration of early harvest extra virgin olive oil as a therapeutic strategy against Alzheimer’s disease, Exp. Gerontol., 144, 111178, 10.1016/j.exger.2020.111178 · DOI
  184. Borowiec, 2021, Flavonoids from edible fruits as therapeutic agents in neuroinflammation—A comprehensive review and update, Crit. Rev. Food Sci. Nutr., 62, 6742, 10.1080/10408398.2021.1905604 · DOI
  185. Khan, 2019, Dietary Supplementation of the Antioxidant Curcumin Halts Systemic LPS-Induced Neuroinflammation-Associated Neurodegeneration and Memory/Synaptic Impairment via the JNK/NF-κB/Akt Signaling Pathway in Adult Rats, Oxidative Med. Cell. Longev., 2019, 7860650, 10.1155/2019/7860650 · DOI
  186. Sil, 2016, Dual Role of Vitamin C on the Neuroinflammation Mediated Neurodegeneration and Memory Impairments in Colchicine Induced Rat Model of Alzheimer Disease, J. Mol. Neurosci., 60, 421, 10.1007/s12031-016-0817-5 · DOI
  187. Devassy, 2016, Omega-3 Polyunsaturated Fatty Acids and Oxylipins in Neuroinflammation and Management of Alzheimer Disease, Adv. Nutr., 7, 905, 10.3945/an.116.012187 · DOI · Paper page
  188. Sun, 2020, Effect of Clostridium butyricum against Microglia-Mediated Neuroinflammation in Alzheimer’s Disease via Regulating Gut Microbiota and Metabolites Butyrate, Mol. Nutr. Food Res., 64, 1900636, 10.1002/mnfr.201900636 · DOI · Paper page
  189. Ribarič, S. (2022). Physical Exercise, a Potential Non-Pharmacological Intervention for Attenuating Neuroinflammation and Cognitive Decline in Alzheimer’s Disease Patients. Int. J. Mol. Sci., 23. · DOI
  190. Song, 2018, Treadmill exercise and wheel exercise improve motor function by suppressing apoptotic neuronal cell death in brain inflammation rats, J. Exerc. Rehabil., 14, 911, 10.12965/jer.1836508.254 · DOI
  191. Liu, 2020, Short-term resistance exercise inhibits neuroinflammation and attenuates neuropathological changes in 3xTg Alzheimer’s disease mice, J. Neuroinflamm., 17, 4, 10.1186/s12974-019-1653-7 · DOI
  192. Zhang, 2022, Treadmill exercise improve recognition memory by TREM2 pathway to inhibit hippocampal microglial activation and neuroinflammation in Alzheimer’s disease model, Physiol. Behav., 251, 113820, 10.1016/j.physbeh.2022.113820 · DOI

Cited by

See all 202

Metadata

Authors
Al-Ghraiybah, N. F., Wang, J., Alkhalifa, A. E., Roberts, A. B., Raj, R., Yang, E., & Kaddoumi, A.
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2022-09-12
Volume
23
Issue
18
Pages
10572
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4295846926
Cited by
202
References
103
FWCI
10.68
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glial Cell-Mediated Neuroinflammation in Alzheimer’s Disease. https://app.cochat.ai/papers/10.3390/ijms231810572
The paper
Al-Ghraiybah, N. F., Wang, J., Alkhalifa, A. E., Roberts, A. B., Raj, R., Yang, E., & Kaddoumi, A. (2022). Glial Cell-Mediated Neuroinflammation in Alzheimer’s Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms231810572

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.